Pyrazolopyrimidine jak inhibitor compounds and methods

A compound of Formula Ia:

• enantiomers, diastereomers or pharmaceutically acceptable salts thereof, wherein:
• R1 is H;
• R2 is —OR4, —NR3R4, —NR3NR12R4, —NR3S(O)R4 or —NR3S(O)2R4;
• R3 is H or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, wherein said alkyl, alkenyl and alkynyl are optionally substituted by oxo, F, ORa or NRaRb;
• R4 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —(C0-C5 alkyl)(C1-C9 heterocyclyl), —(C0-C5 alkyl)(C3-C6 cycloalkyl), —(C0-C5 alkyl)(C1-C9 heteroaryl), —(C0-C5 alkyl)(C6-C10 aryl), wherein said alkyl, alkenyl and alkynyl are optionally substituted by R8, and said aryl, cycloalkyl, heteroaryl and heterocyclyl are optionally substituted by R9;
• or
• R3 and R4 are taken together with the nitrogen to which they are attached to form a C1-C9 heterocyclyl optionally substituted by R13;
• Z is —OR6 or —NR5R6;
• R5 is H or C1-C3 alkyl;
• R6 is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, —(C0-C5 alkyl)(C1-C9 heterocyclyl), —(C0-C5 alkyl)(C3-C8 cycloalkyl), —(C0-C5 alkyl)(C1-C9 heteroaryl), —(C0-C5 alkyl)(C6-C9 aryl), wherein said alkyl, alkenyl and alkynyl are optionally substituted by R10, and said aryl, cycloalkyl, heteroaryl and heterocyclyl are optionally substituted by R1;
• R7 is H, halo, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl or —O(C1-C3 alkyl);
• R8 is independently oxo, halo, ORa or NRaRb;
• R9 is independently oxo, —CN, —CF3, halo, —C(O)C1-C6 alkyl, —C(O)ORa, —C(O)NRaRb, —(C0-C5 alkyl)NRaRb, —(C0-C5 alkyl)ORa, —(C0-C5 alkyl)SRa, —O[C(Ra)2]1-3O—, C1-C3 alkyl optionally substituted by oxo or F, —(C0-C5 alkyl)(C3-C6 cycloalkyl) optionally substituted by oxo or F, —(C0-C5 alkyl)C1-C9 heterocyclyl optionally substituted by halo, oxo, C1-C3 alkyl or C(O)C1-C3 alkyl, —(C0-C5 alkyl)C6 aryl optionally substituted by halo or C1-C3 alkyl —O(C1-C3 alkyl), or —(C0-C5 alkyl)C1-C9 heteroaryl optionally substituted by halo or C1-C3 alkyl;
• R10 is independently oxo, halo, ORa or NRaRb;
• R11 is independently oxo, —CN, —CF3, halo, —O[C(Ra)2]1-3O—, —C(O)C1-C6 alkyl, —C(O)ORa, —C(O)NRaRb, —(C0-C5 alkyl)NRaRb, —(C0-C5 alkyl)ORa, C1-C6 alkyl optionally substituted by oxo or F, —(C0-C5 alkyl)C1-C9 heterocyclyl optionally substituted by halo, oxo, C1-C3 alkyl or C(O)C1-C3 alkyl, —(C0-C5 alkyl)C1-C9 heteroaryl optionally substituted by halo or C1-C3 alkyl, —(C0-C5 alkyl)phenyl optionally substituted by C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkynyl, C3-C6 cycloalkyl, —CF3, halo, —CN, —ORa or —NRaRb, or —(C0-C5 alkyl)C3-C6 cycloalkyl optionally substituted by oxo, —NRcRd, C1-C3 alkyl or F;
• R12 is H or C1-C3 alkyl;
• R13 is oxo, halo, C1-C3 alkyl, —C(O)C1-C6 alkyl, —C(O)ORa, C6 aryl, C3-C6 cycloalkyl, C1-C5 heteroaryl or C4-C5 heterocyclyl;
• wherein said aryl, cycloalkyl, heteroaryl and heterocyclyl are optionally substituted by C1-C4 alkyl, —(C0-C3 alkyl)ORc, oxo, halo or NRcRd;
• Ra and Rb are independently H, —CF3, —CHF2, —CH2F, C1-C6 alkyl, C6 aryl, C3-C6 cycloalkyl or C4-C5 heterocyclyl;
• wherein said alkyl, aryl and cycloalkyl are optionally substituted by C1-C4 alkyl, —(C0-C3 alkyl)ORc, oxo, halo, NRcRd or C4-C5 heterocyclyl;
• or
• Ra and Rb together with the atom to which they are attached form a C1-C5 heterocyclyl optionally substituted by oxo, F, C1-C3 alkyl, —C(O)C1-C6 alkyl or —C(O)ORa;
• and
• Rc and Rd are independently H, C1-C3 alkyl, C3-C6 cycloalkyl or phenyl, wherein said alkyl, cycloalkyl and phenyl are optionally substituted by halo, CH3OH, NH2, C(O)O(C1-C6 alkyl) or C(O)NH(C1-C6 alkyl).